Home > News content

"Lancet" announced the results of phase I / II of China's biological new coronavirus vaccine: both immunity and safety are good

via:博客园     time:2020/10/16 17:20:11     readed:751

There will soon be 40 million new coronavirus patients in the world. If we want to control it, we can only rely on the popularization of vaccines in the future. On the new coronavirus vaccine, the lancet, the world's top medical journal, recently published the results of phase I / II of China's biological new coronavirus vaccine, showing good immune and safety performance.

The results showed that neutralizing antibodies could be effectively induced and had good immunogenicity. The neutralizing antibodies induced by vaccines could neutralize a variety of virus strains, including the current natural mutant strain d614g with mutants.

For vaccines, in addition to the immune effect, the safety can not be ignored. The lancet paper shows that the new coronavirus vaccine of China biology is safe in human body, mainly due to pain at the injection site, followed by fever, but they are mild and self limiting, and do not need any treatment.

《柳叶刀》公布中国生物新冠病毒疫苗I/II

China biology is a subsidiary of China Pharmaceutical Group. Wuhan Institute of biological products and Beijing Institute of biological products respectively launched two kinds of inactivated vaccines in April this year, which are also one of the earliest vaccines to enter clinical phase I / II trials in the world.

In June this year, a total of 2240 people were enrolled in the phase I / II clinical trial of China biological inactivated vaccine. The blinds were opened on June 16 and 28, respectively. The results showed that the vaccine was safe and had no obvious adverse reactions. High titer immune response was produced after vaccination with different ages, procedures and doses.

Two kinds of new crown inactivated vaccines are leading the world in safety, effectiveness and other product performance.

Previously, Liu Jingzhen, Secretary of the Party committee and chairman of sinopharma group, disclosed in an interview with the media that the dose of a vaccine is 4 μ g, and the protection rate of one dose of vaccine is about 97%. After two injections of vaccine, the protection rate can reach 100%. After the new crown inactivated vaccine is put on the market, the price is expected to be several hundred yuan per injection.

According to the data, Sinopharm group produces 50 kinds of vaccine of product specifications annually, with an annual output of more than 700 million doses and a market share of 80%. It is China's largest and the world's sixth adult vaccine production and research enterprise, with four national technology centers and six provincial and municipal enterprise technology centers.

In 2019, the company's scientific research investment reaches 1.484 billion yuan, accounting for 12.3% of the sales volume, and the annual average scientific research investment proportion exceeds the domestic industry level.

《柳叶刀》公布中国生物新冠病毒疫苗I/II

China IT News APP

Download China IT News APP

Please rate this news

The average score will be displayed after you score.

Post comment

Do not see clearly? Click for a new code.

User comments